Retatrutide Vs Semaglutide: What The Evidence Suggests About Muscle Loss

March 3, 2026

GLP-1 medications have changed what's possible in weight management, and they've also changed the questions patients ask in clinic. One of the most common (and most reasonable) concerns is this: "Am I losing muscle?" In the current wave of interest around next-generation drugs, "retatrutide vs semaglutide muscle loss" has become a popular comparison point.

From a medical standpoint, the most accurate framing is that any substantial weight loss, no matter how it's achieved, can reduce lean mass. GLP-1 therapy can accelerate fat loss by lowering appetite and calorie intake, but without a plan for protein and resistance training, some of the weight lost may come from lean tissue. This article reviews what the evidence actually shows for semaglutide and what early data suggests for retatrutide, then focuses on what truly determines muscle preservation in real life.

Why Muscle Loss Happens During GLP-1-Driven Weight Loss

Muscle loss during GLP-1-driven weight loss isn't a "side effect" unique to the medication as much as it is a predictable biology problem: a sustained calorie deficit changes what the body chooses to keep and what it chooses to spend.

GLP-1 therapies (like semaglutide) reduce hunger, slow gastric emptying for many patients, and can make portions naturally smaller. That's often the goal. But when total energy intake drops quickly, especially alongside nausea, food aversions, or skipped meals, protein intake tends to fall too. And when dietary protein and resistance training aren't sufficient, the body has less signal to preserve muscle.

Lean Mass Vs Muscle: What Studies Actually Measure

A major source of confusion in the "muscle loss" conversation is the measurement itself.

Most clinical trials report changes in lean body mass (LBM) using DEXA scans. LBM is not the same thing as "pure muscle." It includes:

Skeletal muscle
Organ tissue
Water content
Glycogen (stored carbohydrate)
Other non-fat components (and DEXA also estimates bone separately)

So when a trial reports "39% of weight lost came from lean mass," it does not automatically mean 39% of the weight lost was functional contractile muscle. Early in weight loss, people also lose glycogen and associated water, which shows up as lean mass reduction.

Still, over months, some portion of LBM loss can reflect true muscle loss, especially when protein is low and strength training is absent.

Calorie Deficit, Protein Intake, And Resistance Training As The Main Drivers

Across obesity medicine and sports nutrition research, three variables explain most of the variance in muscle retention during weight loss:

Size and speed of the calorie deficit (bigger/faster deficits increase lean loss)
Protein intake (higher protein supports muscle protein synthesis)
Resistance training (the strongest "keep this muscle" signal the body understands)

For many adults on GLP-1s, the practical targets that repeatedly show up as protective are:

Protein: roughly 1.6–2.0 g/kg/day (often adjusted for goals and tolerability)
Resistance training:2–3 sessions/week focusing on major movement patterns

In other words: the medication influences appetite: the lifestyle plan determines how "selective" the weight loss is.

Semaglutide And Lean Mass: What Clinical Trials And Real-World Data Show

Semaglutide is the best-studied medication in this conversation, so it's the most honest place to start. The data consistently shows substantial fat loss, alongside measurable lean mass reduction.

In the STEP-1 trial (a landmark semaglutide obesity trial), body composition analyses suggested that about 39–40% of the weight lost was from lean body mass, with the remainder largely from fat mass. That ratio is not wildly different from what clinicians see with many effective weight-loss approaches, especially when weight loss is rapid or when participants aren't specifically coached to lift and hit protein targets.

Real-world experiences often look similar but more variable. People who:

lose very quickly,
struggle with nausea or food aversion,
or "forget to eat" on busy days

tend to under-consume protein and total calories, which raises the odds of losing more lean mass than they expected.

How Much Weight Loss Is Typically Lean Mass

Across GLP-1 and related therapies, a commonly reported range is ~25–40% of total weight lost coming from lean mass.

For semaglutide specifically, the STEP-1 body composition sub-analyses are often summarized as:

~60% fat mass loss
~40% lean mass loss (LBM)

That "40%" number understandably alarms patients, but it needs interpretation:

Some lean mass reduction is fluid/glycogen-related, especially early.
The clinically important question is whether strength, function, and muscle performance are declining.
The ratio can improve meaningfully with protein + progressive resistance training.

Who Appears Most Vulnerable: Older Adults, Low Protein Intake, Sedentary, Rapid Loss

Not everyone has the same risk profile for muscle loss on semaglutide. In practice, the most vulnerable groups tend to include:

Older adults, who have more age-related anabolic resistance (harder time building/maintaining muscle)
People with low protein intake due to appetite suppression, GI symptoms, or dietary pattern
Sedentary individuals (no resistance training stimulus)
Those losing weight very rapidly (often cited as more than ~1–2 lb/week on average, especially if sustained)

For women 35–55, especially in perimenopause/menopause, this topic is extra important because baseline muscle mass and strength may already be trending downward due to hormonal shifts, sleep disruption, and changes in activity. GLP-1s can be excellent tools, but they work best when paired with a muscle-preserving plan from day one.

Retatrutide And Lean Mass: What Early Data Can And Cannot Tell Us Yet

Retatrutide is generating attention because it's not "just another GLP-1." It's a triple-agonist (GLP-1, GIP, and glucagon receptor activity), and early trials have reported very large average weight loss.

But when it comes to retatrutide vs semaglutide muscle loss, the key phrase is: early data.

In phase 2 research (48-week data), retatrutide produced impressive total weight loss, and body composition analyses suggested roughly:

~67% of weight lost from fat mass
~33% from lean body mass (LBM)

That may look slightly more "fat-selective" than the commonly cited STEP-1 semaglutide ratio (~60/40). But, comparing across trials is tricky.

Why Triple-Agonism Could Change Weight-Loss Composition

Mechanistically, triple-agonism is interesting because glucagon receptor activity may increase energy expenditure and shift substrate utilization. In theory, that could:

reduce the degree to which the body needs to "borrow" from lean tissue during a deficit,
improve fat oxidation,
or change the pace and pattern of weight loss.

That's the physiological rationale behind the idea that retatrutide might preserve muscle slightly better than semaglutide.

Still, physiology plausibility is not the same as proof.

Limitations Of Current Retatrutide Body-Composition Evidence

At the time of writing, important caveats remain:

Much of the publicly discussed retatrutide composition data comes from phase 2 work.
There is no large, definitive head-to-head trial versus semaglutide reporting DEXA outcomes in a directly comparable way.
Retatrutide is not FDA-approved (clinical availability and safety monitoring differ from established therapies).
DEXA reports lean mass, not direct muscle fiber metrics or strength outcomes.

So while retatrutide may eventually prove to be more fat-selective, the most responsible clinical message today is: lean mass loss can still occur, and the patient's nutrition/training plan is likely to matter more than the drug label.

Head-To-Head Perspective: What Matters More Than The Drug Name

Patients often want a simple verdict: Which medication causes less muscle loss?

Based on current evidence, the most accurate answer is: the difference between people is often larger than the difference between drugs.

Yes, early retatrutide data suggests a potentially better fat-to-lean loss ratio (e.g., ~67/33) compared with commonly cited semaglutide estimates (~60/40). But both sit in the broader GLP-1 range where ~25–40% of weight lost may be lean mass.

In clinic, the bigger drivers of whether someone "looks smaller but feels weaker" versus "looks leaner and feels stronger" usually come down to pace, protein, and training consistency.

Rate Of Loss, Dose Escalation, And Duration

Two patients can take the same medication and have opposite body-composition outcomes.

Key variables include:

Rate of loss: Slower tends to be more muscle-preserving. A commonly used guardrail is aiming for <~1 kg/week on average, though individual goals vary.
Dose escalation: Gradual titration can reduce nausea and help patients maintain protein intake.
Duration at very low intake: Weeks of "I can only manage a yogurt and some crackers" is a muscle-loss setup.

The clinical pearl: muscle is expensive tissue. If the body senses sustained under-fueling and no mechanical demand (lifting), it down-regulates muscle.

Metabolic Context: Prediabetes/Diabetes, Menopause, And Baseline Muscle

Baseline physiology changes the risk-benefit equation.

Prediabetes/diabetes: Insulin resistance and higher inflammation can complicate muscle maintenance. Improving metabolic health helps, but protein distribution and training remain essential.
Perimenopause/menopause: Shifts in estrogen can accelerate loss of lean mass and strength: sleep quality and recovery may worsen, too.
Baseline muscle: People starting with lower muscle mass (or with a long history of dieting and minimal strength work) have less "reserve."

So the head-to-head question, retatrutide vs semaglutide muscle loss, often becomes a more practical one: How can the patient protect lean mass given their appetite, GI tolerance, schedule, and hormonal/metabolic context?

A Practical Muscle-Preserving Plan While On Semaglutide Or Retatrutide

A muscle-preserving plan has to fit GLP-1 reality: appetite may be low, fullness may come fast, and some days protein is simply unappealing. The strategy is not perfection, it's repeatable structure.

Protein Targets And Timing For GLP-1 Users With Low Appetite

A medically reasonable target for many adults in active weight loss is ~1.6–2.0 g/kg/day, individualized for kidney function, overall calories, and clinician guidance.

The sticking point is execution. For GLP-1 users, protein often works better when it is:

Front-loaded earlier in the day (before appetite fades)
Split into smaller "protein anchors" instead of two huge meals
Built around tolerable textures (shakes, yogurt, eggs, soups) when solid food is tough

Practical pattern many patients can manage:

25–35 g protein at breakfast
25–35 g protein at lunch
25–35 g protein at dinner
10–25 g protein as a "bridge" snack if needed

For patients with IBS, reflux, or GLP-1-related GI sensitivity, protein can be harder to tolerate. This is where GI-friendly protein options and slower eating matter.

Casa de Sante's focus on digestive health for GLP-1 users is relevant here: their physician-formulated approach (including gentler, sensitive-stomach-friendly nutrition tools) can help some patients hit protein targets without constantly paying for it with bloating or nausea. A soft starting point is exploring their GLP-1 support line and meal-plan resources at Casa de Sante.

Strength Training Minimums And Progression For Busy Adults

The minimum effective dose is lower than most people think, but it must be consistent.

A practical baseline:

2–3 full-body sessions/week
30–45 minutes each
Emphasis on major patterns: squat/lunge, hinge, push, pull, carry

A "busy adult" template:

Day A: Goblet squat, dumbbell press, row, Romanian deadlift
Day B: Split squat, lat pulldown/assisted pull, push-ups, hip thrust

Progression matters more than novelty. A simple progression rule:

Keep form solid.
Add reps first, then add load.
Track one or two key lifts (e.g., leg press or squat variation, row, press).

If strength is holding steady or increasing while weight drops, the odds of meaningful muscle loss are lower.

Creatine, Fiber, And GI-Friendly Strategies When Protein Is Hard To Tolerate

Supplements won't replace food and training, but they can fill gaps.

Creatine monohydrate: Often used at ~5 g/day. It supports training performance and lean mass in many populations. Some people experience mild water retention or GI upset: starting with smaller doses and taking with food can help.
Fiber strategies: Constipation is common on GLP-1s, and low fiber can worsen appetite irregularity and gut symptoms. But fiber must be introduced carefully, especially for IBS-prone individuals.
GI-friendly protein delivery: Smooth textures (protein shakes, lactose-free options, low FODMAP-friendly choices when appropriate) can improve adherence.

This is another place where a targeted digestive-health approach can make the plan livable. For patients who are juggling GLP-1 nausea, constipation, or IBS symptoms, Casa de Sante's GLP-1 support products and personalized meal plans can be a practical adjunct, less "perfect diet," more "repeatable, tolerated routine."

How To Monitor Muscle And Function Without Overcomplicating It

Monitoring doesn't need to become a second job. The goal is to catch problems early, before someone notices they're weaker, not just smaller.

DEXA, Bioimpedance, Tape Measurements, And Progress Photos: Pros And Cons

DEXA

Pros: One of the best accessible tools for estimating fat mass vs lean mass distribution
Cons: Cost, access, small variability between scans: still measures "lean mass," not pure muscle

Bioimpedance scales (BIA)

Pros: Convenient, trend-friendly if measured consistently
Cons: Highly influenced by hydration, sodium, timing, menstrual cycle

Tape measurements (waist, hip, thigh, upper arm)

Pros: Cheap, surprisingly informative over time
Cons: Requires consistent technique

Progress photos

Pros: Captures body recomposition that the scale misses
Cons: Lighting/angles can mislead: best as a monthly check, not daily scrutiny

A reasonable approach: pick one composition tool (DEXA every 4–6 months or consistent BIA trends) plus tape + photos monthly.

Strength And Function Markers: Grip, Reps, Stairs, And Energy

Function is where muscle matters.

Useful markers include:

Grip strength (simple dynamometer, or clinic-based tracking)
Reps at a fixed weight (e.g., how many goblet squats with 25 lb)
Stairs (time to climb a standard flight without stopping)
Daily energy and recovery (sleep quality, soreness, "heavy legs")

If weight is dropping but strength is stable and energy is improving, that's typically a reassuring pattern.

If weight is dropping and performance is sliding week over week, it's time to adjust calories, protein, training, or medication pacing.

When To Involve Your Clinician Or Dietitian

GLP-1 therapy works best when it's treated like real medical care, not a solo experiment. A clinician or dietitian can help distinguish normal adjustment symptoms from a plan that's quietly going off the rails.

Red Flags: Weakness, Hair Loss, Persistent Nausea, And Unintended Rapid Loss

The following deserve medical attention rather than "pushing through":

Noticeable weakness or declining strength/function
Significant hair shedding (can reflect rapid loss, low protein, low iron, thyroid issues, or other deficiencies)
Persistent nausea/vomiting limiting intake
Unintended rapid loss, often considered >~2 lb/week sustained (context matters)
Dizziness, dehydration, constipation that doesn't respond to basic measures

These don't automatically mean the medication must be stopped, but they do suggest the plan needs adjustment.

Medication, Nutrition, And Training Adjustments That May Help

Clinicians commonly consider:

Slowing dose escalation or holding at a tolerated dose longer
Reviewing total intake to ensure a patient isn't unintentionally eating extremely low calories for weeks
Setting a protein floor and using more tolerable formats (shakes, soups, small frequent meals)
Pairing patients with a dietitian who understands GLP-1 appetite patterns and GI side effects
Modifying training: starting with lower volume but consistent resistance work, then progressing

For patients with sensitive digestion (IBS history, low FODMAP needs, frequent bloating/constipation on GLP-1s), a structured program can make the difference between "I can't hit protein" and "I have a plan I can tolerate." Casa de Sante's physician-built ecosystem, supplements, meal plans, and gut-health tools designed around GLP-1 realities, may be a helpful discussion point to bring to a clinician, especially when nutrition adherence is limited by GI symptoms.

Conclusion

The most honest takeaway from the current "retatrutide vs semaglutide muscle loss" debate is that both medications can be associated with lean mass loss, often landing in a similar ballpark (roughly 25–40% of total weight lost in many analyses). Retatrutide's triple-agonist mechanism may eventually prove to be more fat-selective, but the evidence is still early, not head-to-head, and not a substitute for the fundamentals.

In clinical practice, the best predictor of preserving muscle isn't the drug name, it's whether the person has a realistic plan for protein, progressive resistance training, and a sustainable rate of loss, plus monitoring that focuses on function (strength, stamina, day-to-day energy).

For patients using GLP-1 therapy who are struggling with nausea, constipation, IBS flares, or simply can't tolerate typical "high-protein diet" solutions, it's reasonable to explore digestive-health-focused supports. Casa de Sante's GLP-1-friendly tools and physician-formulated products can fit as a practical adjunct, helping patients stay consistent with nutrition while protecting the long-term goal: not just a lower number on the scale, but a stronger, healthier body.

Frequently Asked Questions (FAQs)

Does retatrutide vs semaglutide cause more muscle loss during weight loss?

In the retatrutide vs semaglutide muscle loss debate, both can be associated with lean mass loss when weight drops quickly. Semaglutide data (STEP-1) suggests ~39–40% of weight lost was lean body mass, while early retatrutide phase 2 data suggests ~33%. Differences between individuals often exceed drug-to-drug differences.

Why does muscle loss happen on semaglutide or other GLP-1 medications?

Muscle loss is usually driven by the calorie deficit, not a unique drug “side effect.” GLP-1 medications reduce appetite and may cause nausea or skipped meals, which can lower protein intake. Without enough protein and resistance training, the body has less reason to maintain muscle while losing weight.

In studies, is “lean mass loss” the same as actual muscle loss?

Not exactly. Most trials use DEXA and report lean body mass (LBM), which includes skeletal muscle plus organs, water, and glycogen. Early in weight loss, glycogen and water drop and appear as lean loss. Over time, low protein and no strength training can turn some LBM loss into true muscle loss.

How can I prevent muscle loss on semaglutide or retatrutide while dieting?

The biggest muscle-sparing factors are protein, resistance training, and a sustainable pace of loss. Many plans target ~1.6–2.0 g/kg/day protein (individualized) and 2–3 full-body strength sessions weekly. Slower loss and gradual dose titration can also help you keep eating enough protein consistently.

What’s a “normal” amount of lean mass loss with GLP-1 weight loss?

Across GLP-1–related therapies, a commonly reported range is ~25–40% of total weight lost coming from lean mass on DEXA. Semaglutide is often summarized near ~60% fat / ~40% lean, while early retatrutide data suggests ~67% fat / ~33% lean—still not head-to-head comparable.

Should I track DEXA scans to monitor retatrutide vs semaglutide muscle loss?

DEXA can be helpful for trends, but it still measures lean mass—not pure muscle or strength. A practical approach is one composition tool (DEXA every 4–6 months or consistent bioimpedance) plus monthly tape measurements and photos, and function markers like grip strength, reps at a fixed weight, stair tolerance, and energy.